LONDON: Benevolent AI, a London-based startup that’s using artificial intelligence to discover new drugs, has received US$115mil in additional funding to hire more people and expand its focus to new diseases.
The latest venture capital investment values the startup at just over US$2bil, the company said yesterday – about a 17% increase compared to estimates during its 2015 financing round.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
